Drugs / DM-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04266028 | Feb 2020 → May 2021 | ragweed sensitivity | Desentum Oy | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-25 | Desentum Oy | Results Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults desentum.fi ↗
Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-25 | Desentum Oy | Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults desentum.fi ↗ |
| 2021-05-11 | Desentum Oy | Dosing completed for Desentum’s First-in-Human clinical study of DM-101 desentum.fi ↗ |
| 2020-11-30 | Desentum Oy | Clinical study with birch pollen hypoallergen DM-101 continues desentum.fi ↗ |
| 2020-03-26 | Desentum Oy | First-in-Human clinical study with DM-101 paused due to corona virus pandemic desentum.fi ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04266028 ↗ |
| Route | Subcutaneous | “DM-101 administered by subcutaneous (SC) injection” NCT04266028 ↗ |